Reinventing life sciences

How emerging ecosystems fuel innovation
A key partner in your life sciences ecosystem

IBM Life Sciences can help you to innovate and explore new partnerships to become active in a more sustainable health system that provides better patient accessibility to treatment. Our solutions enable accelerated product innovation and drive both commercial effectiveness and care management through analytic insights.
Executive summary

The global life sciences industry has faced a series of wake-up calls over the past decade. Yet, despite volatility, the industry has generally continued to deliver successful returns to shareholders. Even so, old and new challenges continue, including untamable cost growth in traditional research and development (R&D), slow time-to-market and ever-growing expectations for value and effectiveness from increasingly empowered consumers – compounded by complex R&D challenges from expiring patents and constraints on cost recovery. So, life sciences companies need to reevaluate the nature of traditional business models, processes and operations.

In fact, the industry is rapidly evolving into a new type of ecosystem model that requires a level of cooperation and inter- and intra-collaboration that organizations have not engaged in before. While there are many potential benefits from participating in the emerging ecosystem, most companies struggle to both understand the full impact of these changes, and take the steps necessary to benefit fully from them.

To help organizations navigate the uncertainty, the IBM Institute for Business Value in collaboration with the University of California, San Diego and Oxford Economics surveyed 750 executives in seven countries and nine life sciences-related areas (see “How we conducted our research” on page 16). We found that most executives acknowledge the needs and benefits of the changing business environment. Yet many are unprepared to prioritize new ways of working that better leverage the expanding life sciences and healthcare ecosystems.

In this first report in a series addressing innovation in the life sciences industry, we conclude that adopting a target innovation model can help organizations reap greater benefits through a more deliberate approach to innovation across the enterprise. A robust model will encourage innovation across the enterprise, including cost-sharing opportunities, expanded capabilities through learning and partnerships, extended reach across industries and markets, and risk sharing in product development and distribution.
Life sciences: Success despite challenges

While the life sciences industry has faced challenges, companies have still been able to produce positive outcomes, delivering to shareholders a premium over the Standard and Poor’s index as a whole for the past five years (see Figure 1). But despite its successes, the industry faces new and difficult challenges including:

- **Intellectual property (IP) rights** – How can companies deal with IP in an environment of fluidly changing connections? Divergent attitudes on IP and its importance in innovation can hold back open innovation. But mechanisms exist to enable partners to balance openness about research results with the ultimate need for a clear IP position on products requiring major investment.

- **Outcomes-based pricing** – This is a fundamental method for driving cost-reducing innovation among healthcare providers and achieving a financially sustainable healthcare system. While already tried and tested in Europe, outcomes-based pricing is still relatively new in the United States.

- **Disease prevention shift** – A shift of payer focus from cure to prevention has resulted in the growth of vaccine sales from a US$12B market in 2006 to US$30B in 2014, with more companies investing in vaccine development, particularly for adult vaccines.

Activity among traditional players and new entrants highlights a change of guard in the life sciences industry. Many large pharmaceutical companies have undergone major changes: 17 of the 50 top pharmaceutical companies from a decade ago have merged or been acquired. And companies from other industries, such as Apple and Google, are beginning to participate in the life sciences as part of their cross-industry go-to-market strategies.
The industry faces challenges, but has still been able to find success. Development

Drug development costs have risen at 2.43 times the inflation rate since the 1970s.

Generics

Generic drug prescriptions capture 84% of market share within the first year of branded drug patent expiration.

Genomes

Over the last decade, the cost to generate a human genome sequence has fallen from US$1 billion to US$3-5 thousand.

Growth

Companies have been created and grown significantly: 20 of the top 50 pharmaceutical companies in 2013 were not ranked in 2004’s top 50.

Figure 1

The industry faces challenges, but has still been able to find success.

The result of all of these influences is that the future for life sciences will look radically different from the past. Imagine this future:

- Organizations can predict and avoid a molecule’s failure in phase III clinical trials before beginning development
- Resources flow freely across organizations where and when they are needed to enable rapid, dynamic innovation
- Late-stage failures are analyzed across the ecosystem to unlock new pathways and discover new combination therapies.

While these capabilities portend a bright future, today many in the life sciences industry are struggling to adapt to the speed and effectiveness of new types of innovation.

The impact of biosimilars

In March 2015, the U.S. Food and Drug Administration (FDA) announced the approval of the first non-brand, complex biopharmaceutical—“biosimilar”—in U.S. pharmaceutical history. Europe has been marketing biosimilars for 10 years now, and the FDA is currently developing long-awaited standards. However, biosimilars are costly to make. And since they will not be identical copies, doctors and patients may be slow to accept them as substitutes.
Emerging ecosystems

New technologies are driving radical disruption – value chains are fragmenting, industries are converging and ecosystems are emerging (see Figure 2). New entrants from other industries are blurring the traditional definition of life sciences:

- Healthcare: University Hospitals is developing new medical technology
- Information technology: Google Ventures is investing heavily in life sciences
- Consumer electronics: Apple has launched iWatch and health apps

As ecosystems continue to evolve, companies have to decide the level and nature of their participation. Ecosystems can provide numerous opportunities for participants and our study shows that many life sciences executives understand this. Life sciences ecosystems possess three major characteristics.

1. **Boundary transcendence:** Ecosystems transcend traditional boundaries – by geography, product/service and industry – helping participants to break down barriers that separate silos. Our study reveals nearly half of respondents (47 percent) of life sciences executives expect that expanding into emerging markets will stimulate industry innovation. And 38 percent expect partnering with organizations from other industries will energize innovation.

For example, Roche and the telecommunications company Qualcomm formed a partnership to improve remote chronic care management and drive patient engagement. With Roche using Qualcomm’s 2net Platform to wirelessly capture data from patients’ medical devices, healthcare professionals can remotely keep in touch with patients, helping reduce therapy complications and total cost of care for chronic disease patients.
2. **Openness**: Ecosystems provide a free flow of ideas, knowledge and resources among participants across the system. Open innovation – the integration of knowledge and expertise from multiple sources to aid in developing new technologies, products and processes – is a defining feature of the life sciences ecosystem. And most respondents recognize the importance of openness: 79 percent of executives say that open innovation plays a role in their innovation process. Sixty-one percent said that it makes the development of ideas better and faster.

AstraZeneca, for example, has started an open innovation program inviting academic researchers to collaborate in new drug development. It grants UK academic investigators free access to the 22 candidate compounds it developed. External researchers are encouraged to submit research proposals for funding to further develop these compounds into new drugs. Within one year of making these compounds available, the Medical Research Council awarded £7 million in funding for 15 research projects.¹⁰

3. **Collaboration**: The emerging life sciences ecosystem is profoundly collaborative, allowing organizations to communicate, act and work in new ways. These fluid, ongoing relationships are built over time through partnering on new drugs and other projects with mutual value. Life sciences executives are looking to build their ecosystem by pursuing these types of collaborations (see Figure 3).

Shire Pharmaceuticals entered into a five-year research collaboration in rare diseases with Fondazione Telethon (a charity focused on curing rare genetic diseases), coupling Telethon Institute of Genetics and Medicine’s early-stage research expertise with Shire’s capital and developmental capabilities.¹¹ The collaboration between Shire and Fondazione can help accelerate the development of new therapies.
Taking charge of innovation

So, what can an organization do to gain these benefits? It can introduce a target innovation model to start down the path of strategic and systematic innovation. The target innovation model comprises eight elements: strategy; culture; processes; organization and governance; collaboration and connectivity; skills and capabilities; tools and assets; and performance metrics (see Figure 4).

**Figure 4**
*Target innovation model within the life sciences ecosystem*

“In order to advance the business model, we need to use an open innovation platform for both the inflow and outflow of knowledge.”

Faculty member located in China for academic institution headquartered in the US
1. Strategy

Align innovation business plans and policies

Today, most life sciences organizations do not have an integrated approach to innovation across their business. And the industry could not see this more clearly: of the 750 life sciences executives surveyed, an alarming 100 percent recognized at least some mismatch between their organization’s prevailing strategy and its research activities (see Figure 5).

Recommendations: Strategy

Organizations need to more clearly align business and innovation strategies. To help facilitate the alignment of strategy to drive innovation, they can:

- Direct specific innovation efforts by appointing a head of innovation, either in the C-suite or reporting directly to an influential member of the C-suite, to support oversight of the entire innovation portfolio.
- Review the innovation profile of all businesses in your organization and consider alternatives for those that do not fit the innovation strategy.
- Develop an inclusive innovation strategy driven from the top that covers business and areas across the value chain – from research through clinical and pharmaceutical development, through technology transfer and production into sales and marketing.

Figure 5

Without exception, industry executives recognize a rift between research and the prevailing strategy of the organization.

Source: 2014 Life Sciences Innovation Survey. Question: To what extent do you agree with the statement “Research is not aligned with strategic initiatives of the business?”

- Completely agree: 22%
- Moderately agree: 23%
- Strongly agree: 55%

7
2. Culture

Create an environment that fosters innovation

Creating a culture and environment that encourages and supports innovation across and beyond the organization is paramount for repeatable innovation. Executives agree that poor culture can impede innovation (see Figure 6). Seventy percent of leaders in life sciences agree that the culture of their organization makes it difficult to be innovative.

Recommendations: Culture

Organizational culture should encourage all employees to behave innovatively and conceive innovative ideas. To operate effectively in an ecosystem, organizations need to create environments that support innovation in all areas of the business, not solely R&D. To be open to the internal and external influences that can promote idea generation, organizations must create an atmosphere for all employees that fosters confidence, creativity, engagement, enthusiasm, flexibility, a sense of urgency and a willingness to explore. Specifically:

- Demonstrate that innovation is not just the domain of R&D scientists by building a culture of innovation around the patient’s needs or opportunities, rather than focus on specific drugs.
- Build innovation into the day-to-day activities of employees, giving them time, space, environments and tools to collaborate and share new ideas.
- Encourage employees to reach outside their “four walls” to experience other innovative cultures and bring the best parts back into the organization; for example, innovation clubs or tours of duty in other organizations (even potentially in other industries).
3. Processes

Create structure to support innovation
Formal processes and a structured approach to innovation can direct and facilitate development of ideas without stifling creativity. But our survey suggests much of the industry lacks the structure needed (see Figure 7).

Recommendations: Processes
Creating and communicating innovation processes and structures to employees and ecosystem partners can spur more innovation. Innovation processes should be formed to support the major steps of the innovation cycle. For example:

- Develop creative ways of sourcing new ideas, both across and from outside the company. Use social media, attend conferences, join organizations outside the life sciences industry or participate in local communities and engage with local, regional or international bodies.
- Verify that innovation processes are transparent, consistent and communicated to everyone who participates in them. Take a birds-eye view of all ideation projects across the organization, and share selection and evaluation criteria and information on the innovation portfolio itself.
- Roll out treatment, operations processes or new business models. Implement processes that help ensure new initiatives remain aligned with business priorities.

Throughout the entire process, organizations must be willing to stop projects that do not meet standards to avoid draining resources from the innovation portfolio.

Source: 2014 Life Sciences Innovation Survey. Questions: (a) and (b) What barriers to innovation do you see for your organization? (c) Thinking of how your organization deals with innovation, does your organization treat innovation projects as part of an overall portfolio or a series of one-off projects?
4. Organization and governance

Facilitate and manage innovative projects
Today, executives report that their innovation projects struggle to generate momentum within their organizations. Thirty-seven percent of life sciences executives say that innovation projects suffer from organizational inertia, which creates resistance to innovation. Organizational inertia ranks third out of 12 barriers to innovation in the life sciences industry.

Recommendations: Organization and governance
Create a dedicated innovation SWAT team to manage, guide and support cross-organization innovation. In addition, form an innovation oversight team of senior leadership from across the organization to make decisions on funding and oversight of the innovation portfolio. Steps these teams can take:

- Build the expertise and skills needed to run effective ideation sessions and innovation processes, including facilitation skills, financial skills, creative and operational capabilities. Representation should be from both inside and outside the organization.
- Survey leading practices in innovation management and introduce new innovation models, including incubator/“side” organizations or other entrepreneurial models that might comprise part of an overall innovation strategy.
- Build structure that looks within and beyond the organization for innovation ideas and opportunities that fit with the innovation portfolio.

Innovating R&D productivity
AstraZeneca adopted a “5R Framework” for innovation project approval decisions. The 5R Framework defines five “gates” of approval for R&D projects: right target, right tissue/exposure, right safety, right patients, and right commercial application.

Employing this framework has reduced the size of the company’s innovation portfolio, allowing them to focus resources on projects that have already passed approval gates and therefore have a higher chance of success. Having a defined R&D approval process has improved AstraZeneca’s innovation project success rate by eliminating projects that do not pass initial approval checkpoints.

AstraZeneca adopted a “5R Framework” for innovation project approval decisions. The 5R Framework defines five “gates” of approval for R&D projects: right target, right tissue/exposure, right safety, right patients, and right commercial application.

Employing this framework has reduced the size of the company’s innovation portfolio, allowing them to focus resources on projects that have already passed approval gates and therefore have a higher chance of success. Having a defined R&D approval process has improved AstraZeneca’s innovation project success rate by eliminating projects that do not pass initial approval checkpoints.
5. Collaboration and connectivity

Build new relationships
Open collaboration across and between organizations is critical to innovating in the age of ecosystems. Our findings show that a lack of collaboration across organizations is a barrier to innovation. Sixty-four percent of executives for example, report that their organization struggles to establish partnering relationships.

Recommendations: Collaboration and connectivity
Collaboration is the building block of ongoing relationships. How can companies prepare for collaborating in an ecosystem?

- Get to know how new players in the ecosystem work and partner (for example, electronics companies for medical devices), and draw lessons from a partner’s own unique methods and models.
- Initiate innovation advisory groups that include a range of ecosystem players, including the end users (such as patients and care-givers).
- Confirm that goals of new innovation projects and collaborations are shared, understood and agreed upon before kick-off.

Collaborating to create innovative products
University of California Center for Accelerated Innovation (UC CAI) is a consortium of the five University of California medical campuses with the objective to create innovative new products to benefit patients. It has been designated a Center for Accelerated Innovations by the National Heart, Lung and Blood Institute (NHLBI). The five campuses accounted for 7 percent of NHLBI’s fiscal year 2012 grant funding, providing a rich research base to support a diverse pipeline of diagnostics, devices, therapeutics, and tools for heart, lung and blood diseases.
6. Skills and capabilities

Connect the right people with the right skills
Organizations struggle to connect the right individuals with the right skills and capabilities necessary to innovate. Life sciences is known for its brilliant scientists, but many organizations lack true innovators. Thirty-nine percent of executives report that they have insufficient skilled human resources or the wrong skills portfolio for innovation.

Recommendations: Skills and capabilities
Organizations must find and nurture individuals with the necessary capabilities to conceive and develop ideas. To verify that people fit with and support the organization’s objectives and direction:

- Recruit and plant “innovation seeds” from outside the life sciences industry; for example, bring “best practice thinking” from the auto industry to innovate the technology transfer process.
- Recognize the level of support and training needed to convert ideas into results. Not everyone is an innovator, but everyone can have a good idea.
- “Cross-pollinate” skills across the organization. Bring together teams of scientists from research labs, process engineers from manufacturing and sales reps who interact with doctors to drive innovation focused at the end user.
7. Tools and assets

Provide the right material
Providing the necessary tools and assets to employees can help facilitate and support innovation efforts. Life sciences executives have underestimated the value of tools that help employees to innovate. Only 40 percent stated that using social media as a tool to identify and evaluate ideas is very important to their innovation efforts today, and just 34 percent said that big data and analytics is an important adjunct to successful innovation today.

Recommendations: Tools and assets
Many different tools can support innovation in different ways. Specific tools relevant to the organization’s innovation can be investigated and adopted to:

• Extract insights from available information to support ideation processes, and innovation development, refinement and launch.
• Enable accessibility of innovation platforms and tools within and outside the organization, while complying with industry compliance and regulatory standards.
• Enable rapid and reliable transfers of information through collaboration and knowledge sharing.

IBM Watson diagnoses cancer
IBM Watson leverages cognitive analytics to synthesize structured and unstructured data to support faster, more accurate diagnoses. Watson technologies access patient profiles to rapidly analyze high volumes of medical documentation to diagnose medical conditions with great accuracy. Over time, Watson’s artificial intelligence capabilities and analytics improve accuracy as it develops a knowledge base and learns from both mistakes and successes. In a recent test, Watson successfully diagnosed lung cancer 90 percent of the time—compared to only 50 percent for doctors.
Monitor innovation projects

The IBM Institute for Business Value study, “More than magic: How the most successful organizations innovate,” concludes that innovation projects should be monitored and measured with clear financial and other metrics, the same as any other project. Yet, only 31 percent of life sciences executives said that having a clear focus on performance is crucial to the success of innovation (see Figure 8).

Recommendations: Performance metrics

Clear performance metrics allow life sciences organizations to quantify outcomes and the effectiveness of innovation, making it easier to prioritize projects on the basis of their success, and helping decisions about continuing funding. Specifically, organizations should:

- Evaluate innovation across various stage-gates with financial and other quantitative and qualitative criteria.
- Develop a shared set of outcome and activity metrics that are acceptable and achievable by all ecosystem partners.
- Demonstrate how and where value has been created across the entire lifecycle of projects, providing real-time feedback interaction with other projects in the innovation portfolio.

Figure 8

Across the industry, organizations use various ways to measure success of innovations.

<table>
<thead>
<tr>
<th>Metric</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy of new products</td>
<td>47%</td>
</tr>
<tr>
<td>Patient sentiments</td>
<td>51%</td>
</tr>
<tr>
<td>Quality of care for patients</td>
<td>37%</td>
</tr>
<tr>
<td>Gaining volume market share</td>
<td>39%</td>
</tr>
<tr>
<td>Gaining revenue market share</td>
<td>32%</td>
</tr>
</tbody>
</table>

Source: 2014 Life Sciences Innovation Survey. Question: Please select the factors that you use to evaluate success of your organization’s innovations.
Are you ready to thrive in the ecosystem?

Life sciences has been one of the most successful global industries for a generation. But many of the incumbent organizations have succeeded so well in the traditional life sciences model that they are struggling to find a new path within the profound disruption that the industry is beginning to experience. Unless they change, they will either be subsumed by new and more dynamic players or simply cease to be.

In the emerging life sciences and healthcare ecosystems, organizations require a renewed focus on their strengths as they prepare to play new and different roles. They need to reinvent the industry’s traditional innovation heritage. The following questions can help them get started:

• What role does your organization currently plan to play in life sciences?
• What is your approach to innovation today?
• How will you formalize operational processes to promote more innovation in future life sciences and healthcare ecosystems?
• How can you cultivate the skills and capabilities within your workforce to innovate for openly, collaboratively and effectively?
• What will be your most effective innovation processes and tools in the new era of ecosystems?

“Innovation can come from anywhere and anyone. Some of the best ideas and solutions are residing outside your company and hence it’s very important to have an open business model.”

Research leader located in the UK for a biotech company
How we conducted our research
The survey, designed by the IBM Institute for Business Value and the University of California at San Diego, was conducted by Oxford Economics with 750 respondents, including 255 pharmaceutical, 154 biotechnology, 152 academic, 106 medical device, 34 medical services, 33 diagnostic manufacturer, 12 medical distributor, 3 generics producer and 1 consumer healthcare respondent. It was conducted in October and November of 2014 in seven countries: Belgium, China, Germany, Japan, Switzerland, United Kingdom and the United States.

About the authors
Heather Fraser is a pharmacist with over 30 years of industry experience in pharmaceutical R&D, consultancy and community pharmacy. She leads the Life Sciences and Healthcare team at the IBM Institute for Business Value, where she has published extensively on the future of the life sciences, healthcare and the emergence of the healthcare ecosystem. Heather has a strong interest in partnering and alliance management between pharmaceutical, biotech and academic organization – topics that she has researched, published and consulted on over the past 15 years. Heather holds an MBA from the University of Warwick. She can be contacted at hfraser@uk.ibm.com.

Anthony Marshall is Strategy Leader and Program Director of the Global CEO Study for the IBM Institute for Business Value. Previously, Anthony led numerous projects in the IBM Strategy and Innovation Financial Services Practice, focusing on business strategy and innovation. Anthony has consulted extensively with U.S. and global clients, working with numerous top-tier organizations in innovation management, digital strategy, transformation and organizational culture. He has also worked in regulation economics, privatization and M&A. Anthony has more than 20 years of consulting, research and analytical experience. He can be reached at anthony2@us.ibm.com.

Teri Melese, PhD, currently holds the position of Assistant Vice Chancellor, Industry Research Alliances in the Office of Research Affairs at University of California, San Diego. She is also an Associate Professor in Medicine and, the Rady School of Management. Teri is a thought leader in academic/industry partnering strategy and has authored several articles in this area in high-profile journals. Previously, she has run an independent research laboratory and was a founding member of a venture-backed startup company, Iconix Biosciences. She has four patents to her name and holds an A.B., a Ph.D. and was an American Cancer Senior Postdoctoral Fellow – all at the University of California. Teri is available at tmelese@ucsd.edu.
Contributors
Lauren O’Donnell, Global General Manager and Vice President – Life Sciences, IBM Sales and Distribution
David Root, Consultant – Business Transformation, IBM Global Business Services
Timothy Dietlin, Partner – Life Sciences R&D, IBM Global Business Services
Maria Elena Morales, Senior Consultant – Life Sciences, IBM Global Business Services

Acknowledgments

Related publications


For more information
To learn more about this IBM Institute for Business Value study, please contact us at iibv@us.ibm.com. Follow @IBMIBV on Twitter and for a full catalog of our research or to subscribe to our monthly newsletter, visit: ibm.com/iibv

Access IBM Institute for Business Value executive reports on your phone or tablet by downloading the free “IBM IBV” app for iOS or Android from your app store.

The right partner for a changing world
At IBM, we collaborate with our clients, bringing together business insight, advanced research and technology to give them a distinct advantage in today’s rapidly changing environment.

IBM Institute for Business Value
The IBM Institute for Business Value, part of IBM Global Business Services, develops fact-based strategic insights for senior business executives around critical public and private sector issues.
References


